Functionally different tenascin (TN) isoforms. containing varying numbers of a 9 I amino-acid motif resembling the fibronectin type-Ill homology repeat, may be generated by alternative splicing of the TN primary transcript. In fact, only the TN isoform containing the alternatively spliced region can
Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues
β Scribed by Janusz Kaczmarek; Patrizia Castellani; Guido Nicolo; Bruno Spina; Giorgio Allemanni; Luciano Zardi
- Publisher
- John Wiley and Sons
- Year
- 1994
- Tongue
- French
- Weight
- 953 KB
- Volume
- 59
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
β¦ Synopsis
Two different oncofetal fibronectins (FN) have been reported: one, generated by 0-glycosylation in the splicing region lllCS that is recognized by monoclonal antibody (MAb) FDC-6, and another, recognized by MAb BC-I, generated by the alternative splicing of the FN pre-mRNA which includes an extra type-Ill repeat called ED-B. Using these and 2 other MAbs (IST-4 which recognizes all different FN isoforms and IST-6 which recognizes only the FN molecules that do not include the ED-B sequence) we have immunohistochemically studied I 7 I normal, hyperplastic and neoplastic breast-tissue specimens.
Although all normal specimens reacted strongly with MAbs IST-4 and IST-6, they did not show the presence of oncofetal FNs as established by the use of BC-l and FDC-6. In contrast, out of the 97 cases of invasive ductal carcinomas studied, 90 (93%) and 96 (99%) reacted positively with BC-I and FDC-6, respectively, the reaction being observed in the tumoral stroma connective tissue and in tumoral vessels. Furthermore, invasive lobular carcinoma showed less intense and less frequent staining with BC-I and FDC-6 (10 and I I out of 14, respectively). We found differences in the distribution of the 2 oncofetal fibronectin isoforms within the same specimens. The most remarkable difference was observed in the tumoral vessels: in invasive ductal carcinoma MAb BC-l revealed a positive reaction with vessels in 78% of cases while FDC-6 showed such a reaction in only 59% of cases.
π SIMILAR VOLUMES
Descriptions for tenascin-C distribution are largely restricted to epithelial tumours. The present study utilized newly developed and characterized monoclonal (hT191) and polyclonal antibodies to investigate the distribution pattern of tenascin-C in a panel of mesenchymal tumours, which was contrast